The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype. Stage 3a lung cancer is often treated with surgery and medicines before or after surgery. Stage 3b and 3c ...
The approval was based on the results of CheckMate 816, an international, multiregional, active-controlled trial that randomly assigned 358 patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (N2 ...
Keytruda, a PD-1 inhibitor, is now approved for early-stage NSCLC, improving disease-free survival post-surgery and chemotherapy. Immunotherapy's role in NSCLC treatment is expanding, with Keytruda ...
A total of 5,016 patients were included. Most patients were between 60 and 69 years old (33.6%) and had completed elementary school (52.2%). There was a greater proportion of men (58.1% v 41.9%), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results